|Awarded On||November 16, 2016|
|Title||Oncolytic Immunotherapy for Gliomas and Cancer Metastases in the Era of Checkpoint Regulation|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Juan Fueyo|
|Cancer Sites||Brain and Other Nervous System, Breast, Lung and Bronchus, Melanoma|
At the end of last year, an oncolytic herpesvirus that induces an immune response against cancer cells became the first therapy of its kind to be approved for use in the United States, paving the way for a long-awaited class of treatments for cancer. On 27 October 2015, the US Food and Drug Administration (FDA) approved a genetically-engineered virus called talimogene laherparepvec (T-VEC) to treat advanced melanoma. Four days earlier, advisors to the European Medicines Agency had endorsed the drug. After many years of step-by-step improvements of the virotherapy/immunotherapy strategy, many scientists believe that the era of the oncolytic virus is probably here. In 2005, regulators in China...